A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 36; no. 15_suppl; p. e15138
Main Authors	Xu, Jianming, Qin, Shukui, Zhang, Yun, Zhang, Yaoyue, Jia, Ru, Liu, Rongrui, Wang, Yan, Zhang, Gairong, Zhao, Chuanhua, Lu, Ni, Ma, Xiaoyu, He, Yue, Yuan, Liwei, Lin, Yihui, Xu, Wenlian, Wang, Xiaoxiao, Wang, Pilin, Xu, Ting, Dong, RuiPing, Gong, John
Format	Journal Article
Language	English
Published	20.05.2018
Online Access	Get full text

Loading…